AngioDynamics (ANGO) Projected to Post Earnings on Thursday

AngioDynamics (NASDAQ:ANGO) is expected to announce its Q1 2027 results before the market opens on Thursday, October 8th. Analysts expect the company to announce earnings of ($0.1125) per share and revenue of $80.51 million for the quarter. AngioDynamics has set its FY 2027 guidance at -0.290–0.240 EPS. Interested persons are encouraged to explore the company’s upcoming Q1 2027 earning overview page for the latest details on the call scheduled for Thursday, October 8, 2026 at 8:00 AM ET.

AngioDynamics (NASDAQ:ANGO) last issued its earnings results on Tuesday, July 14th. The medical instruments supplier reported ($0.07) EPS for the quarter, beating analysts’ consensus estimates of ($0.11) by $0.04. AngioDynamics had a negative net margin of 11.48% and a negative return on equity of 5.73%. The business had revenue of $86.61 million for the quarter, compared to the consensus estimate of $80.24 million. On average, analysts expect AngioDynamics to post $-0 EPS for the current fiscal year and $-0 EPS for the next fiscal year.

AngioDynamics Trading Down 7.2%

Shares of AngioDynamics stock opened at $14.42 on Wednesday. AngioDynamics has a twelve month low of $9.39 and a twelve month high of $16.29. The stock has a market cap of $606.36 million, a price-to-earnings ratio of -16.57 and a beta of 0.30. The company has a fifty day moving average price of $15.47 and a 200 day moving average price of $13.08.

Insider Buying and Selling at AngioDynamics

In related news, SVP Warren Jr sold 23,370 shares of AngioDynamics stock in a transaction on Thursday, July 30th. The stock was sold at an average price of $14.72, for a total transaction of $344,006.40. Following the completion of the sale, the senior vice president owned 64,745 shares of the company’s stock, valued at approximately $953,046.40. This trade represents a 26.52% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Company insiders own 6.00% of the company’s stock.

Wall Street Analyst Weigh In

A number of equities research analysts have recently issued reports on ANGO shares. Weiss Ratings reiterated a “sell (d-)” rating on shares of AngioDynamics in a research note on Friday, July 17th. HC Wainwright lifted their target price on AngioDynamics from $16.00 to $19.00 and gave the stock a “buy” rating in a research report on Wednesday, July 15th. Zacks Research lowered shares of AngioDynamics from a “hold” rating to a “strong sell” rating in a research note on Thursday, July 16th. Canaccord Genuity Group raised their target price on AngioDynamics from $16.00 to $20.00 and gave the company a “buy” rating in a research note on Wednesday, July 15th. Finally, Wall Street Zen upgraded AngioDynamics from a “hold” rating to a “buy” rating in a research report on Saturday, August 22nd. One analyst has rated the stock with a Strong Buy rating, two have assigned a Buy rating and two have given a Sell rating to the company. According to MarketBeat.com, the stock has an average rating of “Hold” and a consensus target price of $19.50.

About AngioDynamics

AngioDynamics, Inc is a medical device company that develops, manufactures and markets minimally invasive products for use in vascular disease, vascular access and oncology. Its technologies are designed to help physicians treat blood clots, restore blood flow, manage vascular access and ablate targeted tissue.

The company’s portfolio includes the Auryon platform for atherectomy, which uses laser technology to treat peripheral arterial disease; the AngioVac and AlphaVac systems for removing thrombus and other unwanted material from blood vessels; and BioSentry products used to seal biopsy tracts.